Axsome Therapeutics (AXSM) Profit After Tax (2015 - 2026)

Axsome Therapeutics has reported Profit After Tax for 12 years, with the latest figure at -$64.5 million in Q1 2026.

• Quarterly Profit After Tax fell 8.63% year-over-year to -$64.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$188.3 million (up 32.33% YoY) and the FY2025 annual result came in at -$183.2 million, up 36.22% from the prior year.
• Profit After Tax declined to -$64.5 million in Q1 2026 per AXSM's latest filing, from -$28.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $125.7 million in Q4 2022 and troughed at -$98.7 million in Q4 2023.
• A 5-year average of -$45.6 million and a median of -$59.4 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax soared 469.91% in 2022, then sank 509.35% in 2024.
• Over 5 years, Profit After Tax stood at $125.7 million in 2022, then sank by 178.49% to -$98.7 million in 2023, then advanced by 24.06% to -$74.9 million in 2024, then jumped by 61.88% to -$28.6 million in 2025, then plunged by 126.0% to -$64.5 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$64.5 million, -$28.6 million, and -$47.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.